IMV (IMVIF) EBITDA Margin %: 0.00% (As of Dec. 2022)


IMVIF IMV Inc IMVIF
12 GF Score
Price $0.00
View Full Analysis

What is IMV EBITDA Margin %?

IMV IMVIF -99.95% 12 EBITDA Margin % is 0.00% as of Dec. 2022. GuruFocus rates IMVIF with a GF Score™ of 12/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. IMV's EBITDA for the three months ended in Dec. 2022 was $-8.27 Mil. IMV's Revenue for the three months ended in Dec. 2022 was $0.00 Mil. Therefore, IMV's EBITDA margin for the quarter that ended in Dec. 2022 was 0.00%.


IMV  (OTCPK:IMVIF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


IMV EBITDA Margin % Related Terms


IMV EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for IMV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IMV EBITDA Margin % Chart

IMV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24,748.33 -43,546.67 0.00 0.00 0.00

IMV Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IMVIF vs RGTPQ, QBIO, RGIN: EBITDA Margin % Comparison

For the Biotechnology subindustry, IMV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IMV EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IMV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where IMV's EBITDA Margin % falls into.


IMVIF
12GF Score
IMV Inc IMVIF
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IMV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

IMV's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-37.49/0
= %

IMV's EBITDA Margin % for the quarter that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2022 )/Revenue (Q: Dec. 2022 )
=-8.268/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
IMV (IMVIF) has a EBITDA Margin % of 0.00% as of Dec. 2022. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IMV and its competitors.
Is IMV's EBITDA Margin % too high?
IMV's current EBITDA Margin % is 0.00%. Overall, IMV has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does IMV's EBITDA Margin % compare to RGTPQ and QBIO?
IMV's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IMV and its competitors. IMV's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IMV stock overvalued right now?
IMV (IMVIF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. IMV's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For IMV (IMVIF), the current EBITDA Margin % is 0.00% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IMV Business Description

Address 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, NS, CAN, B3B 2C4
IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Its proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system.
12GF Score

Get the complete analysis for IMVIF

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price